The estimated Net Worth of Hung Do is at least $15.4 Million dollars as of 14 December 2020. Hung Do owns over 111,125 units of Amicus Therapeutics Inc stock worth over $4,617,116 and over the last 11 years he sold FOLD stock worth over $8,169,915. In addition, he makes $2,605,630 as Chief Scientific Officer at Amicus Therapeutics Inc.
Hung has made over 21 trades of the Amicus Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 111,125 units of FOLD stock worth $2,653,665 on 14 December 2020.
The largest trade he's ever made was exercising 193,700 units of Amicus Therapeutics Inc stock on 9 October 2020 worth over $1,973,803. On average, Hung trades about 17,774 units every 38 days since 2014. As of 14 December 2020 he still owns at least 409,682 units of Amicus Therapeutics Inc stock.
You can see the complete history of Hung Do stock trades at the bottom of the page.
Dr. Hung Viet Do Ph.D. serves as Chief Scientific Officer of the Company. Previously, he served as the Company’s Senior Vice President, Discovery Biology since December 2013. Prior to joining Amicus, Dr. Do was a co-founder and Chief Scientific Officer of Callidus Biopharma, Inc. (“Callidus”), a privately held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof of concept for ERTs and served as the project leader for a second generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals, Inc., which was acquired by Genzyme. Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University and was a post-doctoral fellow in Hematology/Oncology at Emory University.
As the Chief Scientific Officer of Amicus Therapeutics Inc, the total compensation of Hung Do at Amicus Therapeutics Inc is $2,605,630. There are 3 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Hung Do is 52, he's been the Chief Scientific Officer of Amicus Therapeutics Inc since 2015. There are 15 older and 5 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Hung's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA, PA, 19104.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris, and Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: